New approaches to weight loss and glycaemic control in T2DM, focusing on tirzepatide and newer agents

Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol 2016;4(6):525-36. https://doi.org/10.1016/S2213-8587(15)00482-9

Marx n, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation 2022;146:1882–94. https://doi.org/10.CIRCULATIONAHA.122.059595

Gough SCL. Liraglutide: from clinical trials to clinical practice. Diabetes Obes Metab 2012:14(Suppl2):33-40. https://doi.org/10.1111/j.1463-1326.2012.01576.

Ostawal A, Mocevic E, Kragh N, Xu W. Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review. Diabetes Ther 2016;7(3):411-38. https://doi.org/10.1007/s13300-016-0180-0

Alruwaili H, Dehestani B, Roux C. Clinical impact of liraglutide as a treatment of obesity. Clin Pharmacol 2021;13:53–60. https://doi.org/10.2147/CPAA.S276085

Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22. https://doi.org/10.1056/NEJMoa1411892

Wharton S, Liu A, Pakseresht A, et al. Real‐world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada. Obesity (Silver Spring) 2019;27(6):917–24. https://doi.org/10.1002/oby.22462

Singh N, Stewart RAH, Benatar JR. Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials. BMJ Open 2019;9 (8):e029966. https://doi.org/10.1136/bmjopen-2019-029966

Ahmann A, Chow F, Fonseca V, et al. Superior glycaemic control with semaglutide across SUSTAIN 1-5 clinical trials. Diabetologia 2017;60(1):S377 | added to CENTRAL: 30 November 2017 | 2017 Issue 11. https://doi.org/10.1007/s00125-017-4350-2

Menzen M, Berentzen TL, Catarig AM, Pieperhoff S, Simon J, Jacob 15. Real-world use of once-weekly semaglutide in type 2 diabetes: results from SemaglUtide Real-world Evidence (SURE) Germany. Exp Clin Endocrinol Diabetes 2023;131(4):205–15. https://doi.org/10.1055/a-2007-2061

Wilding JP, Batterham RL, Calanna S, et al for the STEP 1 study group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989-1002. https://doi.org/10.1056/NEJMoa2032183

Davies M, Færch L, Jeppesen OK, et al. STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021; 397(10278):971-84. https://doi.org/10.1016/S0140-6736(21)00213-0.

Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021;325(14):1403-13. https://doi.org/10.1001/jama.2021.1831.

Rubino D, Abrahamsson N, Davies M, et al for STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325(14):1414-25. https://doi.org/10.1001/jama.2021.3224

Garvey WT, Batterham RL, Bhatta M et al, STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine 2022;28:2083–91. https://doi.org/10.1038/s41591-022-02026-4

Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double- dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol 2022;10:193-206. https://doi.org/10.1016/S2213-8587(22)00008-0

Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomised clinical trial. JAMA 2022;327(2):138–50. https://doi.org/10.1001/jama.2021.23619

Ghusa W, De la Rosa A, l Sacoto D, et al. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open 2022;5(9):e2231982. https://doi.org/10.1001/jamanetworkopen.2022.31982

Pelle MC, Provenzano M, Zaffina I, et al. Role of a dual Glucose- dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in glycemic control: from pathophysiology to treatment. Life (Basel) 2022;12(1):29. https://doi.org/10.3390/life12010029

Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:503-15. https://doi.org/10.1056/NEJMoa2107519

Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 2021; 398(10300):583-98. https://doi.org/10.1016/S0140-6736(21)01443-4

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-16. https://doi.org/10.1056/NEJMoa2206038

Garvey WT, Frias JP, Jastreboff AM et al, SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023; 402(10402):613-26. https://doi.org/10.1016/S0140-6736(23)01200-X.Epub 2023 Jun 26

Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine 2023;29:2909–18. https://doi.org/10.1038/s41591-023-02597-w

Aronne LJ, Sattar N, Deborah B, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity. JAMA 2024;331:38-48. https://doi.org/10.1001/jama.2023.24945

Knop FK, Aroda VR, D do Vale R, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;402(10403):705-19. https://doi.org/10.1016/S0140-6736(23)01185-6